Included in the formulation
Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):VED
АТХ:S.01.H.A Local Anesthetics
S.01.H.A.02 Oxibuprocaine
Pharmacodynamics:Local anesthetic (weak base) in non-ionized form (blood pH 7.4) penetrates through the cell membrane into the axon and ionizes there. Ionized molecules of matter interact with specific sites of binding of sodium channels from the inside of the membrane and, blocking sodium channels, interfere with Na + entry into the cell and depolarize the membrane. As a result, the generation of the action potential and the propagation of impulses along the nerve fiber are violated.
Does not affect the size of the pupil and its ability to accommodation. After instillation it is easily absorbed through the mucous membranes. Has an insignificant irritant effect on the conjunctiva.
Pharmacokinetics:Well absorbed with topical application, superficial anesthesia of the conjunctiva and cornea after the application of eye drops occurs after 30-60 seconds and lasts 10-20 minutes.
Indications:Local anesthesia in ophthalmology: measurement of intraocular pressure (tonometry); gonioscopy;diagnostic scrapings of the conjunctiva; extraction of foreign bodies and stitches from the cornea and conjunctiva; short-term surgical interventions on the cornea and conjunctiva.
XXI.Z00-Z13.Z01.0 Examination of eyes and eyesight
XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified
XXI.Z40-Z54.Z40 Prophylactic surgical intervention
Contraindications:Hypersensitivity, erosion of the cornea, children's age (up to 2 years).
Carefully:When taking the drug, protect the eyes from bacterial contamination and dust.
Pregnancy and lactation:Category FDA not determined. During pregnancy and during breastfeeding, the prescribing physician may be used if the expected effect of therapy exceeds the potential risk to the fetus and the child (there is insufficient experience of use).
Dosing and Administration:Dosing regimen is individual. Local application.
Bury the conjunctival sac 1 drop; for diagnostic procedures - 1-2 times, for prolonged anesthesia (up to 1 h) for outpatient surgical interventions, you can additionally instill the drug 3-4 times with an interval of 4-5 minutes.
Side effects:Local: blurred vision, burning, flushing; damage to the corneal layer of the epithelium, infiltration of the corneal stroma; allergic reactions; rarely - keratitis and erosion of the surface of the cornea.
Are common: with increased systemic absorption - anxiety, agitation, nervousness, paresthesia, dizziness, ringing in the ears, blurred vision, nausea, vomiting, convulsions and tremor of muscles; numbness of the tongue and perioral region, sensation of lightness in the head that occurs after sedation (a sign of systemic toxicity); transient excitation, followed by depression, drowsiness, respiratory failure and coma; myocardial depression, peripheral vasodilation, leading to hypotension and bradycardia; arrhythmia and cardiac arrest, allergic reactions, anaphylactic shock.
Overdose:Symptoms: irritation, insomnia, nausea, vomiting, convulsions, respiratory failure, coma, hypotension, cardiac arrest.
Treatment: symptomatic.
Interaction:The drug enhances the effect of succinylcholine and sympathomimetics and reduces the effects of sulfonamides and beta-blockers, is incompatible with silver nitrate, with substances of an alkaline nature, with a solution of fluorescein, since it contains hexidine diacetate, which forms a precipitate upon interaction.
Special instructions:With prolonged use of the drug, damage to the cornea is possible.
Use only for instillations in the conjunctival sac; Do not use for injection. It is not intended for long-term therapy in the complex treatment of eye diseases.
Sufficient experience of use in children is not available, it is possible to use the prescribing physician.
It should be borne in mind that prolonged, repeated and prolonged use can lead to clouding of the cornea (as in the case of other local anesthetics). Do not touch the eyes before the end of the anesthesia.
Influence on ability to driving motor transport and management moving mechanisms.
During the administration of the drug should refrain from the management of transport and moving machinery.